Skip to content

Deferred Taxes at other companies

Avanos Medical logo
Avanos MedicalAVNS
$5.6M0.0%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-14.5%
Enterprise value$1.21B+2.6%
P/E183.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredIncomeTaxLiabilitiesNet.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s deferred taxes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s deferred taxes?
Pacira BioSciences, Inc. (PCRX) reported deferred taxes of $4.09M in Q1 2026.
How has Pacira BioSciences, Inc.'s deferred taxes changed year-over-year?
Pacira BioSciences, Inc.'s deferred taxes decreased by 41.5% year-over-year, from $7M to $4.09M.
What does deferred taxes mean?
This represents the net amount of income taxes that will be payable in future periods due to temporary differences between the carrying amount of assets and liabilities for financial reporting and their tax bases. It reflects the long-term tax impact of accounting choices and depreciation schedules. Investors use this to understand future tax obligations and the impact of tax timing on cash flow.